member
Sean FENG
Co-Founder, Z-Omics Ltd
I am a PhD student in Bioengineering, specializing in microfluidics, with a focus on developing innovative platforms for biomedical applications. Prior to my doctoral studies, I earned an MPhil degree from the Hong Kong University of Science and Technology (HKUST), where I honed my expertise in designing microscale systems for precise fluid manipulation and diagnostics. My research bridges engineering principles with biological challenges, aiming to advance tools for disease modeling, point of-care diagnostics, and high-throughput drug screening. My work integrates advanced fabrication techniques, computational modeling, and experimental validation to create scalable microfluidic solutions. I am particularly passionate about translating lab-scale innovations into practical technologies that address unmet clinical needs. With a strong foundation from HKUST and ongoing doctoral research, I am committed to contributing to the intersection of engineering and healthcare through interdisciplinary collaboration and impactful science.
Company Description
Founded in March 2023, Z-Omics is a young and dynamic biotechnology startup pioneering single-cell multi-omics analysis through our cutting-edge protocol and microfluidics technologies. With our proprietary multi-omics single-cell platform, our mission is to illuminate the unseen layers of cell heterogeneity, accelerate discoveries and drive toward better health and wellbeing. Our HKUST-cofounders leverage state-of-the-art platforms and deep interdisciplinary expertise to create unique single-cell solutions that provide new insights into life science and human health. Z-Omics applies their proprietary technology in single-cell genomics and microfluidics to provide solutions for customers in biological and medical research, as well as pharmaceutical discovery. Single-cell technology measures the genome and other molecular features of individual cells, which reveals the differences and interactions among cells in various biological contexts, providing insights into new biomarkers discoveries, diseases diagnostics, medical treatment monitoring and new therapies development. The application of microfluidics further simplifies the separation process, making the protocol efficient and user-friendly. Moreover, our microfluidics innovatively integrate different types of assays, enabling us to perform high-throughput high-content drug screening to identify potential therapeutic targets for various diseases.